Colorectal cancer screening comparing no screening, immunochemical and guaiac fecal occult blood tests : a cost-effectiveness analysis
Copyright © 2010 UICC..
Comparability of cost-effectiveness of colorectal cancer (CRC) screening strategies is limited if heterogeneous study data are combined. We analyzed prospective empirical data from a randomized-controlled trial to compare cost-effectiveness of screening with either one round of immunochemical fecal occult blood testing (I-FOBT; OC-Sensor®), one round of guaiac FOBT (G-FOBT; Hemoccult-II®) or no screening in Dutch aged 50 to 75 years, completed with cancer registry and literature data, from a third-party payer perspective in a Markov model with first- and second-order Monte Carlo simulation. Costs were measured in Euros (€), effects in life-years gained, and both were discounted with 3%. Uncertainty surrounding important parameters was analyzed. I-FOBT dominated the alternatives: after one round of I-FOBT screening, a hypothetical person would on average gain 0.003 life-years and save the health care system €27 compared with G-FOBT and 0.003 life years and €72 compared with no screening. Overall, in 4,460,265 Dutch aged 50-75 years, after one round I-FOBT screening, 13,400 life-years and €320 million would have been saved compared with no screening. I-FOBT also dominated in sensitivity analyses, varying uncertainty surrounding important effect and cost parameters. CRC screening with I-FOBT dominated G-FOBT and no screening with or without accounting for uncertainty.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2011 |
|---|---|
| Erschienen: |
2011 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:128 |
|---|---|
| Enthalten in: |
International journal of cancer - 128(2011), 8 vom: 15. Apr., Seite 1908-17 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
van Rossum, Leo G M [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
9000-29-7 |
|---|
| Anmerkungen: |
Date Completed 18.04.2011 Date Revised 03.03.2016 published: Print ISRCTN: ISRCTN57917442 Citation Status MEDLINE |
|---|
| doi: |
10.1002/ijc.25530 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM199213496 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM199213496 | ||
| 003 | DE-627 | ||
| 005 | 20231223214207.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231223s2011 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1002/ijc.25530 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0664.xml |
| 035 | |a (DE-627)NLM199213496 | ||
| 035 | |a (NLM)20589677 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a van Rossum, Leo G M |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Colorectal cancer screening comparing no screening, immunochemical and guaiac fecal occult blood tests |b a cost-effectiveness analysis |
| 264 | 1 | |c 2011 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 18.04.2011 | ||
| 500 | |a Date Revised 03.03.2016 | ||
| 500 | |a published: Print | ||
| 500 | |a ISRCTN: ISRCTN57917442 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2010 UICC. | ||
| 520 | |a Comparability of cost-effectiveness of colorectal cancer (CRC) screening strategies is limited if heterogeneous study data are combined. We analyzed prospective empirical data from a randomized-controlled trial to compare cost-effectiveness of screening with either one round of immunochemical fecal occult blood testing (I-FOBT; OC-Sensor®), one round of guaiac FOBT (G-FOBT; Hemoccult-II®) or no screening in Dutch aged 50 to 75 years, completed with cancer registry and literature data, from a third-party payer perspective in a Markov model with first- and second-order Monte Carlo simulation. Costs were measured in Euros (€), effects in life-years gained, and both were discounted with 3%. Uncertainty surrounding important parameters was analyzed. I-FOBT dominated the alternatives: after one round of I-FOBT screening, a hypothetical person would on average gain 0.003 life-years and save the health care system €27 compared with G-FOBT and 0.003 life years and €72 compared with no screening. Overall, in 4,460,265 Dutch aged 50-75 years, after one round I-FOBT screening, 13,400 life-years and €320 million would have been saved compared with no screening. I-FOBT also dominated in sensitivity analyses, varying uncertainty surrounding important effect and cost parameters. CRC screening with I-FOBT dominated G-FOBT and no screening with or without accounting for uncertainty | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Randomized Controlled Trial | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 7 | |a Indicators and Reagents |2 NLM | |
| 650 | 7 | |a Guaiac |2 NLM | |
| 650 | 7 | |a 9000-29-7 |2 NLM | |
| 700 | 1 | |a van Rijn, Anne F |e verfasserin |4 aut | |
| 700 | 1 | |a Verbeek, Andre L M |e verfasserin |4 aut | |
| 700 | 1 | |a van Oijen, Martijn G H |e verfasserin |4 aut | |
| 700 | 1 | |a Laheij, Robert J F |e verfasserin |4 aut | |
| 700 | 1 | |a Fockens, Paul |e verfasserin |4 aut | |
| 700 | 1 | |a Jansen, Jan B M J |e verfasserin |4 aut | |
| 700 | 1 | |a Adang, Eddy M M |e verfasserin |4 aut | |
| 700 | 1 | |a Dekker, Evelien |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t International journal of cancer |d 1966 |g 128(2011), 8 vom: 15. Apr., Seite 1908-17 |w (DE-627)NLM000004383 |x 1097-0215 |7 nnns |
| 773 | 1 | 8 | |g volume:128 |g year:2011 |g number:8 |g day:15 |g month:04 |g pages:1908-17 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1002/ijc.25530 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 128 |j 2011 |e 8 |b 15 |c 04 |h 1908-17 | ||